Cubist Systematic Strategies’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.22M | Buy |
+45,541
| New | +$2.82M | 0.01% | 1499 |
|
|
2025
Q2 | – | Sell |
-129,259
| Closed | -$8.21M | – | 3191 |
|
|
2025
Q1 | $8.21M | Buy |
+129,259
| New | +$8.79M | 0.05% | 595 |
|
|
2024
Q3 | – | Sell |
-23,263
| Closed | -$1.92M | – | 3189 |
|
|
2024
Q2 | $1.92M | Buy |
+23,263
| New | +$2.05M | 0.01% | 1363 |
|
|
2023
Q2 | – | Sell |
-1,708
| Closed | -$141K | – | 3842 |
|
|
2023
Q1 | $141K | Sell |
1,708
-148,288
| -99% | -$12M | ﹤0.01% | 3363 |
|
|
2022
Q4 | $11.8M | Buy |
149,996
+87,102
| +138% | +$7M | 0.07% | 389 |
|
|
2022
Q3 | $4.66M | Buy |
62,894
+23,491
| +60% | +$1.69M | 0.03% | 1141 |
|
|
2022
Q2 | $2.57M | Buy |
39,403
+25,832
| +190% | +$1.53M | 0.02% | 1616 |
|
|
2022
Q1 | $858K | Sell |
13,571
-48,935
| -78% | -$2.66M | 0.01% | 2155 |
|
|
2021
Q4 | $3.31M | Buy |
62,506
+43,309
| +226% | +$2.64M | 0.03% | 943 |
|
|
2021
Q3 | $1.35M | Sell |
19,197
-45,124
| -70% | -$2.85M | 0.02% | 1290 |
|
|
2021
Q2 | $4.29M | Buy |
64,321
+19,509
| +44% | +$1.38M | 0.05% | 629 |
|
|
2021
Q1 | $4.97M | Buy |
44,812
+39,518
| +746% | +$4.89M | 0.06% | 456 |
|
|
2020
Q4 | $629K | Sell |
5,294
-10,026
| -65% | -$1.08M | 0.01% | 1653 |
|
|
2020
Q3 | $1.34M | Sell |
15,320
-162,526
| -91% | -$14.2M | 0.02% | 1161 |
|
|
2020
Q2 | $15.9M | Buy |
177,846
+176,143
| +10,343% | +$17.8M | 0.28% | 43 |
|
|
2020
Q1 | $170K | Sell |
1,703
-23,428
| -93% | -$2.54M | ﹤0.01% | 1791 |
|
|
2019
Q4 | $2.89M | Buy |
25,131
+16,095
| +178% | +$1.95M | 0.05% | 552 |
|
|
2019
Q3 | $1.14M | Buy |
9,036
+8,980
| +16,036% | +$1.14M | 0.02% | 922 |
|
|
2019
Q2 | $7K | Sell |
56
-8,778
| -99% | -$864K | ﹤0.01% | 2414 |
|
|
2019
Q1 | $773K | Buy |
8,834
+7,638
| +639% | +$695K | 0.03% | 898 |
|
|
2018
Q4 | $120K | Sell |
1,196
-1,777
| -60% | -$187K | 0.01% | 1723 |
|
|
2018
Q3 | $341K | Sell |
2,973
-25,621
| -90% | -$2.65M | 0.02% | 1078 |
|
|
2018
Q2 | $2.56M | Buy |
28,594
+26,119
| +1,055% | +$2.21M | 0.13% | 186 |
|
|
2018
Q1 | $181K | Sell |
2,475
-6,486
| -72% | -$445K | 0.01% | 1444 |
|
|
2017
Q4 | $520K | Buy |
8,961
+284
| +3% | +$15K | 0.03% | 877 |
|
|
2017
Q3 | $389K | Buy |
8,677
+2,082
| +32% | +$86.5K | 0.02% | 987 |
|
|
2017
Q2 | $260K | Buy |
+6,595
| New | +$271K | 0.02% | 1132 |
|
|
2017
Q1 | – | Sell |
-10,207
| Closed | -$410K | – | 1712 |
|
|
2016
Q4 | $410K | Buy |
10,207
+5,285
| +107% | +$199K | 0.03% | 769 |
|
|
2016
Q3 | $178K | Sell |
4,922
-17,483
| -78% | -$600K | 0.01% | 1305 |
|
|
2016
Q2 | $650K | Buy |
+22,405
| New | +$677K | 0.04% | 627 |
|
|
2015
Q4 | – | Sell |
-9,006
| Closed | -$291K | – | 1825 |
|
|
2015
Q3 | $291K | Buy |
9,006
+2,184
| +32% | +$82.2K | 0.01% | 1249 |
|
|
2015
Q2 | $282K | Buy |
+6,822
| New | +$288K | 0.01% | 1252 |
|
|
2015
Q1 | – | Sell |
-7,694
| Closed | -$288K | – | 1962 |
|
|
2014
Q4 | $288K | Buy |
7,694
+394
| +5% | +$14.4K | 0.02% | 1250 |
|
|
2014
Q3 | $255K | Sell |
7,300
-2,203
| -23% | -$78.6K | 0.02% | 1206 |
|
|
2014
Q2 | $335K | Buy |
+9,503
| New | +$317K | 0.02% | 918 |
|
Other funds holding HAE
RRAM
Cubist Systematic Strategies's HAE Position: Q3 2025 in Review
Cubist Systematic Strategies opened a new position in Haemonetics (HAE) in Q3 2025: 45,541 shares worth $2.22M. The stake represents 0.01% of the portfolio and ranks #1499 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in HAE as recently as Q1 2025.
Cubist Systematic Strategies first reported a position in HAE in Q2 2014 and has held it in 35 quarters since. The position peaked at $15.9M in Q2 2020. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.
- Cubist Systematic Strategies held 45,541 shares of Haemonetics worth $2.22M as of Q3 2025.
- Haemonetics was a new Cubist Systematic Strategies position in Q3 2025.
- Haemonetics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1499 holding.
- Cubist Systematic Strategies first reported a position in Haemonetics in Q2 2014 and has held it in 35 quarters since.
- Cubist Systematic Strategies's Haemonetics position peaked at $15.9M in Q2 2020.
- 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.